Real‐World Clinical Practice of Lecanemab at PUMCH: Focus on Dynamic Imaging and Biomarker Evolution
Six-month lecanemab treatment demonstrated Clinical stabilization with robust amyloid clearance, MRI brain volume reduction, preserved glymphatic function, promising biomarker trends requiring longer observation and favorable safety profile in Chinese patients.
Authors
- J Y Gao
- F. Feng
- Yuyue Qiu (ORCID: https://orcid.org/0000-0002-9712-2404)
- Li Huo (ORCID: https://orcid.org/0000-0003-1216-083X)
- DongJing Li
- Wenjun Wang (ORCID: https://orcid.org/0000-0003-2603-5714)
- Jialu Bao (ORCID: https://orcid.org/0000-0001-9407-3339)
- Yuhan Jiang (ORCID: https://orcid.org/0009-0001-1098-0722)
- Yifei Wang (ORCID: https://orcid.org/0000-0002-1674-4763)
- Xinhua Wan
- Ling Qiu
- Xinying Huang
- Yunfan You
- Yuanheng Li
- Wei Jin
- Tianyi Wang
- Shanshan Chu
- Chenhui Mao
- Liling Dong
- Meiqi Wu
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108414
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00